[Experimental and clinical assessment of myocardial protective effect of a prostacyclin analogue (OP 41483)].
The beneficial effects of a stable prostacyclin analogue (PGI2-A), OP 41483 against myocardial ischemic injury were experimentally and clinically evaluated. In 31P-NMR study, the preischemic treatment with PGI2-A prevented myocardial ATP depletion of rat hearts which were subjected to 20 min global ischemia. In patients with congenital heart disease, the PGI2-A of 300 ng/ml was added to the glucose-insulin-potassium cardioplegia (PGI2-group), and this group was compared to control group without PGI2-A in terms of postoperative maximal leakage of CPK-MB (maxCPK-MB). In patients under 1 yr or patients over 1 yr with aortic cross clamp time exceeded 120 min, the maxCPK-MB was significantly (p < 0.05) reduced as compared to the control. This stable PGI2 analogue has shown significant myocardial protective effects experimentally and also in clinical setting.
Kuki
S
S
Matsuda
H
H
Sawa
Y
Y
Ohtani
M
M
Sasako
Y
Y
Ohtake
S
S
Takami
H
H
Kuratani
T
T
Nakano
S
S
Kawashima
Y
Y
D000818:Animals; D002314:Cardioplegic Solutions / Q000494:pharmacology*; D002675:Child, Preschool; D003402:Creatine Kinase / Q000097:blood; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005947:Glucose / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D007231:Infant, Newborn; D007328:Insulin / Q000494:pharmacology; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D011188:Potassium / Q000494:pharmacology; D011465:Prostaglandins, Synthetic / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
D002314:Cardioplegic Solutions; D007328:Insulin; D011465:Prostaglandins, Synthetic; C030396:glucose-insulin-potassium cardioplegic solution; D011464:Epoprostenol; D003402:Creatine Kinase; D005947:Glucose; C035847:ataprost; D011188:Potassium